Could Retatrutide Break a GLP-1 Weight-Loss Plateau?
Reported by Medscape. Read the original →
The headline suggests that there is a possibility that Retatrutide (LY3437943) could help individuals overcome a weight-loss plateau associated with GLP-1 treatments. The story implies an exploration of Retatrutide's potential effects on weight management. Further details are not provided.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.Human · RCT · 2026
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Human · RCT · 2026
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.Human · RCT · 2026
14 compounds tracked · 344 studies on file · 150 in humans
What the headline doesn't tell you
- Retatrutide (LY3437943) has 34 studies on file, 10 of them in humans, the newest published 2026.
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.